Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Return on Assets (2016 - 2025)

Historic Return on Assets for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to 0.37%.

  • Adma Biologics' Return on Assets rose 1900.0% to 0.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.37%, marking a year-over-year increase of 1900.0%. This contributed to the annual value of 0.48% for FY2024, which is 5700.0% up from last year.
  • Latest data reveals that Adma Biologics reported Return on Assets of 0.37% as of Q3 2025, which was up 1900.0% from 0.39% recorded in Q2 2025.
  • Adma Biologics' Return on Assets' 5-year high stood at 0.45% during Q4 2024, with a 5-year trough of 0.34% in Q1 2021.
  • Its 5-year average for Return on Assets is 0.03%, with a median of 0.12% in 2023.
  • As far as peak fluctuations go, Adma Biologics' Return on Assets crashed by -100bps in 2021, and later soared by 5300bps in 2024.
  • Adma Biologics' Return on Assets (Quarter) stood at 0.28% in 2021, then skyrocketed by 35bps to 0.18% in 2022, then surged by 54bps to 0.08% in 2023, then surged by 640bps to 0.45% in 2024, then dropped by -17bps to 0.37% in 2025.
  • Its Return on Assets stands at 0.37% for Q3 2025, versus 0.39% for Q2 2025 and 0.41% for Q1 2025.